New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
News|Events|January 9, 2025
OPT Congress: Oligonucleotide & mRNA Therapeutics: March 11–12, 2025
Author(s)BioPharm International Editors
This event brings together leading chemists, biologists, toxicologists, CMC experts, regulatory specialists, and technology providers to discuss advances in next-generation therapeutics.
Dates: March 11–12, 2025
Location: Seaport Hotel, Boston, Mass. & Virtual
Description: This event brings together leading chemists, biologists, toxicologists, CMC experts, regulatory specialists, and technology providers to discuss advances in next-generation therapeutics.
Registration:
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.